chronic rhinisinusitis with asthma
Conditions
Interventions
1:Montelukast (10mg, once daily) for 6 months
2:mometasone furoate nasal spray (200ug, once daily) for 6 months
Sponsors
The First Affiliated Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Aged between 18 to 70 years old, male or female, born and lived in China to date; (2) Rhinosinusitis is defined as: inflammation of the nose and the paranasal sinuses characterized by two or more symptoms, one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip), and with or without facial pain/pressure or reduction or loss smell. CRS is defined as more than 12 weeks of symptoms without complete resolution; (3) All patients with CRS must be also concomitant with physician diagnosed asthma. The level of asthma control status should be partly controlled or controlled according to GINA 2012 guideline; (4) All patients should provide informed consent prior to the study and agree to follow-up appointments.
Exclusion criteria
Exclusion criteria: (1) Immunodeficiency diseases, history of head and/or facial trauma, cancer or organ transplant recipients; (2) Pregnancy or lactation; (3) Uncontrolled bronchial asthma; (4) Acute respiratory tract infection within one month before the study; (5) Use of leukotriene receptor antagonist within 3 months before the enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| nasal symptoms visual analog scale (VAS) scores;nasal symptoms visual analog scale (VAS) score; | — |
Secondary
| Measure | Time frame |
|---|---|
| nasal endoscopy score (Lund-Kennedy score); | — |
Countries
China
Contacts
Public ContactJianbo Shi
The First Affiliated Hospital, Sun Yat-sen University
Outcome results
None listed